Tag Archives: FAK

Trial Drug May Boost Mesothelioma Chemotherapy Success

Targeting Mesothelioma Stem Cells with FAK Inhibitors

There’s more evidence that experimental mesothelioma drugs that inhibit focal adhesion kinase (FAK) may have the ability to dramatically improve the effectiveness of chemotherapy for thousands of mesothelioma patients. Verastem, Inc., the developer of the FAK inhibitors VS-6063 and VS-4718, has just published a new paper on the mechanism by which these drugs work in the medical journal Science Translational Medicine. The research describes how FAK inhibitors make certain mesothelioma cells more susceptible to common chemotherapy drugs like Alimta (pemetrexed) and cisplatin. About half of mesothelioma patients are missing a tumor suppressor called merlin, which can be both good and bad news. Unfortunately, cancers that demonstrate merlin loss tend to be particularly aggressive and mesothelioma is known for its aggressiveness. … Continue reading Trial Drug May Boost Mesothelioma Chemotherapy Success »